Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives

Sotagliflozin is a dual sodium–glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D). Sotagliflozin inhibits renal sodium–glucose co-transporter 2 (determining significant excretion of glucose in the urine, in the same way as other, alrea...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cardiovasc Diabetol
Egile Nagusiak: Cefalo, Chiara Maria Assunta, Cinti, Francesca, Moffa, Simona, Impronta, Flavia, Sorice, Gian Pio, Mezza, Teresa, Pontecorvi, Alfredo, Giaccari, Andrea
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2019
Gaiak:
Review
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6393994/
https://ncbi.nlm.nih.gov/pubmed/30819210
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-019-0828-y
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak